Login / Signup

A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity.

Andras BoeszoermenyiLéa BernaleauXudong ChenFelix KartnigMin XieHaobo ZhangSensen ZhangMaeva DelacrétazAnna KorenAnn-Katrin HoppVojtech DvorakStefan KubicekDaniel AletahaMaojun YangManuele RebsamenLeonhard X HeinzGiulio Superti-Furga
Published in: Nature communications (2023)
Dysregulation of pathogen-recognition pathways of the innate immune system is associated with multiple autoimmune disorders. Due to the intricacies of the molecular network involved, the identification of pathway- and disease-specific therapeutics has been challenging. Using a phenotypic assay monitoring the degradation of the immune adapter TASL, we identify feeblin, a chemical entity which inhibits the nucleic acid-sensing TLR7/8 pathway activating IRF5 by disrupting the SLC15A4-TASL adapter module. A high-resolution cryo-EM structure of feeblin with SLC15A4 reveals that the inhibitor binds a lysosomal outward-open conformation incompatible with TASL binding on the cytoplasmic side, leading to degradation of TASL. This mechanism of action exploits a conformational switch and converts a target-binding event into proteostatic regulation of the effector protein TASL, interrupting the TLR7/8-IRF5 signaling pathway and preventing downstream proinflammatory responses. Considering that all components involved have been genetically associated with systemic lupus erythematosus and that feeblin blocks responses in disease-relevant human immune cells from patients, the study represents a proof-of-concept for the development of therapeutics against this disease.
Keyphrases